Home›Trial›NCT06995677

🔬NCT06995677Phase 2RECRUITING

Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

Study Summary

Phase 2 Study of TYRA-300 in FGFR3 Altered Low Grade, Intermediate Risk NMIBC

Conditions

Low-grade NMIBC FGFR Gene Amplification FGFR Gene Alterations FGFR3 Gene Alteration FGFR3 Gene Mutation FGFR3 Gene Fusions

Interventions / Drugs

TYRA-300 60mg TYRA-300 50mg TYRA-300 Dose TBD

View on ClinicalTrials.gov ↗

Sponsor

Tyra Biosciences

Precision Medicine

Study Details

Enrollment90 participants

Primary Completion—

Lead SponsorTyra Biosciences, Inc

Data Retrieved2026-04-11 04:30:22.593408+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.